Drug Approval | December 10, 2021
China approves Brii Bio’s antibody combination to neutralise Covid-19
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
The tablets are indicated for the treatment of pulmonary arterial hypertension
The Uteshiya facility, licensed by Healthium, will exclusively manufacture Healthium’s arthroscopy portfolio, including patented products in India and U.S.
Working under the Ministry of Ayush, NMPB is mandated to coordinate all matters relating to medicinal plants and support policies and programs for growth of trade, export, conservation, and cultivation of medicinal plants
The company plans to expand their capacity to meet the needs of pharma and biotech industries
Fujifilm India will be providing healthcare Imaging devices and equipment’s to increase the standards of the veterinary care in India.
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
Subscribe To Our Newsletter & Stay Updated
